ORIGINAL RESEARCH article

Front. Cardiovasc. Med.

Sec. General Cardiovascular Medicine

Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1604862

This article is part of the Research TopicExploring Molecular Mechanisms and Novel Diagnostics in Cardiovascular Disease TreatmentView all 13 articles

Effect of folic acid and vitamin B12 plus rosuvastatin in the treatment of coronary heart disease combined with hyperlipidemia

Provisionally accepted
  • Daqing Oilfield General Hospital, Daqing, China

The final, formatted version of the article will be published soon.

Objective: To explore the effect of folic acid and vitamin B12 plus rosuvastatin in treating coronary heart disease (CHD) complicated with hyperlipidemia. Methods: One hundred CHD patients combined with hyperlipidemia admitted to our hospital from January 2022 to December 2023 were separated into study group as well as control group. The control group accepted rosuvastatin calcium tablets. The study group received rosuvastatin plus folic acid and vitamin B12. The cardiac function, blood lipid, plasma Hcy, folate and vitamin B12 levels, inflammation, clinical effect along with occurrence of adverse reactions were compared in 2 groups. Results: Compared to before therapy, LVEDD and LVESD levels were declined while LVEF level was elevated in 2 groups after therapy, TC, TG and LDL-C levels were declined while HDL-C level was elevated in 2 groups after therapy, plasma Hcy level was declined while folate and vitamin B12 levels were elevated in 2 groups after therapy, and IL-6, TNF-α along with CRP levels were declined in 2 groups after therapy. Compared to control group, the improvements of the above cardiac function indicators, blood lipid indexes, plasma Hcy, folate and vitamin B12 levels, serum inflammatory markers in the study group were more apparent, the total effective rate in the study group presented better. No difference was seen in the occurrence of adverse reactions between 2 groups. Conclusion: Folic acid and vitamin B12 plus rosuvastatin can effectively improve cardiac function, blood lipid, inflammatory response, and has high safety in treating CHD complicated with hyperlipidemia.

Keywords: coronary heart disease, Hyperlipidemia, Folic Acid, Vitamin B12, Rosuvastatin, cardiac function, Blood lipid

Received: 15 Apr 2025; Accepted: 04 Jun 2025.

Copyright: © 2025 Wang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Tiezheng Wang, Daqing Oilfield General Hospital, Daqing, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.